I doubt it, short squeezes are a big flag for the

I doubt it, short squeezes are a big flag for the SEC to investigate. If mgmt tried to engineer their own short squeeze, it would be a big problem for them. I think the current mgmt is doing what they said they are doing in the last CC, rebuilding respect in medical field and building team around future plans. These small raises are a necessary thing to pay bills and that is all they are. In the past, Cytodyn has shown zero coordination between fund raising and PRs about trial and business development. I would think it would be smart to at least try and put out positive news and then raise cash, but they have not done this in the past. It could be simply because the timing of these events are not able to be coordinated anyway.

I do agree, Mgmt might think the silent treatment is the best, but we investors deserve better. we are now in the window where the issues with the HIV BLA should be resolved and finishing the BLA can be completed. We are way overdue for the NASH results and we still are not sure if Cancer patients are still getting Lerolimab. Additionally, is the Brazil trials re-started? not to mention the NDA's should be producing agreements between both parties by now.